港股异动 | 德琪医药-B(06996)涨超7% ATG-022用于治疗晚期或转移性实体瘤患者的首次临床试验已获准在澳大利亚开展

智通财经网2023-02-02

智通财经APP获悉，德琪医药-B(06996)涨超7%，截至发稿，涨6.17%，报5.85港元，成交额393.83万港元。消息面上，德琪医药发公告称，ATG-022用于治疗晚期或转移性实体瘤患者的首次临床试验(CLINCH试验)的申请已获得悉尼Bellberry人类研究伦理委员会(HREC)批准，澳大利亚药品管理局(TGA)已于2023年1月30日确认了该项目的临床试验通知(CTN)。CLINCH...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2308436095?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20230202/20230202094516_56080.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2023-02-02 09:44","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2308436095","market":"hk","top_or_hot":-1,"title":"港股异动 | 德琪医药-B(06996)涨超7% ATG-022用于治疗晚期或转移性实体瘤患者的首次临床试验已获准在澳大利亚开展","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，德琪医药-B(06996)涨超7%，截至发稿，涨6.17%，报5.85港元，成交额393.83万港元。消息面上，德琪医药发公告称，ATG-022用于治疗晚期或转移性实体瘤患者的首次临床试验(CLINCH试验)的申请已获得悉尼Bellberry人类研究伦理委员会(HREC)批准，澳大利亚药品管理局(TGA)已于2023年1月30日确认了该项目的临床试验通知(CTN)。CLINCH...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/870237.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 德琪医药-B(06996)涨超7% ATG-022用于治疗晚期或转移性实体瘤患者的首次临床试验已获准在澳大利亚开展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 德琪医药-B(06996)涨超7% ATG-022用于治疗晚期或转移性实体瘤患者的首次临床试验已获准在澳大利亚开展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-02 09:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/870237.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，德琪医药-B(06996)涨超7%，截至发稿，涨6.17%，报5.85港元，成交额393.83万港元。消息面上，德琪医药发公告称，ATG-022用于治疗晚期或转移性实体瘤患者的首次临床试验(CLINCH试验)的申请已获得悉尼Bellberry人类研究伦理委员会(HREC)批准，澳大利亚药品管理局(TGA)已于2023年1月30日确认了该项目的临床试验通知(CTN)。CLINCH...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/870237.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03347","symbol_name":"泰格医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/870237.html","article_id":"2308436095","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20230202/20230202094516_56080.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2308436095","pubTimestamp":1675302272,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"德琪医药-B(06996)涨超7%，截至发稿，涨6.17%，报5.85港元，成交额393.83万港元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03347":"泰格医药","BK1191":"制药","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK1574":"生物医药B类股","BK1583":"高瓴概念","06996":"德琪医药-B"},"translate_title":"Hong Kong stocks changed Deqi Medicine-B (06996) rose by more than 7%. The first clinical trial of ATG-022 for the treatment of patients with advanced or metastatic solid tumors has been approved to be carried out in Australia","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1,"06996":1},"content_text":"智通财经APP获悉，德琪医药-B(06996)涨超7%，截至发稿，涨6.17%，报5.85港元，成交额393.83万港元。消息面上，德琪医药发公告称，ATG-022用于治疗晚期或转移性实体瘤患者的首次临床试验(CLINCH试验)的申请已获得悉尼Bellberry人类研究伦理委员会(HREC)批准，澳大利亚药品管理局(TGA)已于2023年1月30日确认了该项目的临床试验通知(CTN)。CLINCH试验目前已获准在澳大利亚开展，并将在近期内启动。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2308436095"}